Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jan 22;42(9):1021–1030. doi: 10.1200/JCO.23.01498

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 1. — (A) Waterfall plot depicting best overall response (RECIST v1.1) to cemiplimab treatment. Each column represents an individual patient. (B) Swimmer plot showing time on cemiplimab treatment and follow-up period; each row represents an individual patient. (C) Spider plot showing the percentage change (RECIST v1.1) in tumor measurements over time; each line represents an individual patient. (D) Pretreatment (left) and post-treatment (right) CT images showing an infiltrative right preauricular mass from CSCC that resolved over time. Fused PET and CT scans with false color added showing a left dorsal nose CSCC before (left) and after (right) cemiplimab treatment. Fused PET and CT scans showing right level II neck adenopathy (left) before and after (right) treatment. ^aDenotes the development of a new lesion at first response assessment. BL, baseline; CSCC, cutaneous squamous cell carcinoma; CT, computed tomography; PET, positron emission tomography.